mounjaro zepbound tirzepatide Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Mounjaro® (tirzepatide) injection and Zepbound®

Lawrence AE, Fallat ME, Hewitt G, Hertweck P, Onwuka A, Afrazi A, et al

Zepbound (tirzepatide) is a GIP and GLP-1 agonist that works in the treatment of people with obesity or with excess weight and weight-related medical problems by activating the receptors for the natural incretin hormones GIP and GLP-1 to decrease food intake and slow gastric emptying

Should I change my injection timing?" The short answer is probably not

Coverage depends on whether the medication is included in your plans formulary and if the prescribed use aligns with FDA-approved indications

Starting with a lower dose helps your body adjust gradually, and most patients see improvements over time

For immediate assistance please call 206-350-7606